Please login to the form below
Destiny Pharma
This page shows the latest Destiny Pharma news and features for those working in and with pharma, biotech and healthcare.
Ex-Pfizer research head Dr David Roblin joins Destiny Pharma
The former head of research at Pfizer's European operations will be medical director at Destiny. ... Anti-microbial drug development company Destiny Pharma has appointed ex-Pfizer research head Dr David Roblin as medical director.
Latest news
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Choosing destiny
Step 1: From history to destiny. Although, in theory, firms can choose between any of the 26 business models shown in figure 1, in practice they are constrained by their history. ... to, for example, Sun Pharma and vice-versa.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Pharma industry appointments
Nick Rodgers joins Destiny Pharma. Clinical stage biotech Destiny Pharma has announced that Nick Rodgers will join the company as its independent non-executive director, effective immediately. ... Sir Nigel Rudd, chairman of Destiny Pharma, said:
-
Ergomed appoints CEO of PrimeVigilance
Petracek will succeed Neil Clark who will become CEO of Destiny Pharma and will remain on Ergomed’s board of PrimeVigilance as a non-executive director and consultant during a transition
-
Destiny Pharma appoints new CEO
Destiny Pharma has appointed Neil Clark as CEO as the Brighton, UK-based firm plans a phase IIb trial for its lead antimicrobial candidate. ... Nigel Rudd, non-executive chairman of Destiny Pharma, said: “I am delighted to welcome Neil Clark as chief
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
